Merck’s Grastek Gets Larger Population, Easier Dosing Than Stallergene’s Oralair
This article was originally published in The Pink Sheet Daily
Executive Summary
Battle of the two new oral grass pollen immunotherapy treatments is likely on hold till next allergy season, however.